P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA

Bevacizumab is registered in the U.S. for the treatment of recurrent glioblastoma based on improved PFS in uncontrolled phase II trials; Recently, a randomized controlled phase II trial studied lomustin, bevacizumab or the combination of both compounds in the treatment of glioblastoma at first recur...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Clement, P.M., Caenepeel, C., Beuselinck, B., Bechter, O.E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2014
विषय:
Poster Presentations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185719/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.352
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन